eFFECTOR Therapeutics Provides Positive Clinical Data Update for Zotatifin and General Corporate Update
Zotatifin continues to show favorable activity profile, including two confirmed partial responses (PR) among seven heavily pretreated subjects who received zotatifin, fulvestrant and abemaciclib (ECBF+A), with good tolerability eFFECTOR to focus on front- …